
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
PBM Reform Within 2026 Appropriations Bill Signed Into Law
2
Most Favored Nation Drug Pricing: Analysis and Implications
3
From CAR T to Gene Therapy, Pharmacists Prepare for What’s Next at the 2026 Tandem Meeting
4
Q&A: First-in-Class NSD2 Inhibitor KTX-1001 Shows Promise in High-Risk Multiple Myeloma
5


























